The School of Pharmacy at the University of Waterloo

Publications – Clinical Applications

Edginton AN, Fotaki N. Oral Drug Absorption in Pediatric Populations In Oral Drug Absorption: Prediction and Assessment, Second Edition. Dressman J, Reppas C eds. Informa Healthcare, 2010: 108-126.

Willmann S, Edginton, AN, Coboeken K, Ahr G, Lippert J. 2009. Risk of codeine treatment during breastfeeding – a quantitative mechanistic modeling study. Clinical Pharmacology and Therapeutics. In Press.

Edginton AN, Ritter L. 2009. Predicting plasma concentrations of bisphenol A in children younger than 2 years of age after typical feeding schedules, using a physiologically based toxicokinetic model . Environmental Health Perspectives. 117(4): 645-652.

Edginton AN, Ahr G, Willmann S, Stass H. 2009. Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically-based pharmacokinetic modelling. Clinical Pharmacokinetics. 48(3): 181-187.

Edginton AN, Theil FP, Schmitt W, Willmann S. 2008. Whole-body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opinion on Drug Metabolism & Toxicology. 4(9): 1143-1152.

Edginton AN, Willmann S. 2008. Physiology-Based Simulations of a Pathological Condition: Prediction of pharmacokinetics in patients with liver cirrhosis. Clinical Pharmacokinetics. 47(11): 743-752.

Schmitt W, Willmann S, Edginton A. 2007. Die Pharmakokinetik mechanistisch simulieren - PBPK-Modellierung zur computergestutzten Vorhersage. PZ-Prisma. 14(2): 73-80.

Vossen M, Sevestre M, Niederalt C, Jang IJ, Willmann S, Edginton AN. 2007. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theoretical Biology and Medical Modelling. 4: 13.

Edginton AN, Willmann S. 2006. Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paediatric & Perinatal Drug Therapy. 7(3): 146-153.

Edginton AN, Schmitt W, Voith B, Willmann S. 2006. A mechanistic approach for the scaling of clearance in children. Clinical Pharmacokinetics. 45(7): 684-704.

Edginton AN, Schmitt W, Willmann S. Application of physiology-based pharmacokinetic and pharmacodynamic modeling towards individualized propofol target controlled infusion. Advances in Therapy. 2006; 23(1): 143-158.

Publications – Model Development

Willmann S, Edginton AN, Kleine-Besten M, Jantratid E, Thelen K, Dressman JB. 2009. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. Journal of Pharmacy and Pharmacology. 61(7):891-9.

Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. 2007. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. Journal of Pharmacokinetics and Pharmacodynamics. 34(3): 401-431.

Willmann S, Edginton AN, Dressman JB. 2007. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharmaceutical Research. 24(7): 1275-1282.

Edginton AN, Schmitt W, Willmann S. 2006. Development and evaluation of a generic physiology-based pharmacokinetic (PBPK) model for children. Clinical Pharmacokinetics. 45(10): 1013-1034.

Publications – Environmental Toxicology

Thompson DG, Solomon K, Wojtaszek BF, Edginton AN, Stephenson GR. Relyea, R. 2006. The impact of insecticides and herbicides on the biodiversity and productivity of aquatic communities. Ecological Applications. 16(5): 2022-2027.

Edginton AN, Stephenson GR, Rouleau C, Boermans H. 2006. 2,4-D butoxyethyl ester kinetics in embryos of Xenopus laevis: the role of the jelly embryonic jelly coat in reducing chemical absorption. Archives of Environmental Toxicology and Chemistry. 52(1): 113-120.

Edginton AN, Rouleau C. 2005. Toxicokinetics of 14C-atrazine and its metabolites in stage-66 Xenopus laevis. Environmental Science and Technology. 39(20): 8083-8089.

Edginton AN, Sheridan PM, Boermans HJ, Thompson DG, Holt JD, and Stephenson GR. 2004. A comparison of two factorial designs, a complete 3x3 factorial and a central composite rotatable design, for use in binomial response experiments in aquatic toxicology. Archives of Environmental Contamination and Toxicology. 46(2): 216-223.

Edginton AN, Sheridan PM, Stephenson GR, Boermans HJ, and Thompson DG. 2004. pH effects on the toxicity of Vision® herbicide to two life stages of four amphibian species. Environmental Toxicology and Chemistry. 23(4):815-822.

Edginton AN, Sheridan PM, Stephenson GR, Thompson DG, and Boermans HJ. 2003. Effect of pH and Release® on two life stages of four anurans. Environmental Toxicology and Chemistry. 22(11): 2673-2678.

Publications – Others

Szeitz A, Edginton AN, Peng HT, Cheung B, Riggs KW. 2010. A Validated Enantioselective Assay for the Determination of Ibuprofen in Human Plasma Using Ultra Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS). American Journal of Analytical Chemistry. 2: 47-58.

Edginton AN, Holbrook J. 2010. A Blended Learning Approach to Teaching Basic Pharmacokinetics and the Significance of Face-to-Face Interaction. American Journal of Pharmaceutical Education. 74(5): 88.

Patents

Willmann S, Edginton AN, Schmitt W. Verbessertes Verfahren zur zeitlich gesteuerten intravenösen Verabreichung des Narkosemittels Propofol (Improved method and technique for controlled intravenous administration of the sedative propofol). Systems Biology, Bayer Technology Services, Leverkusen, Germany. Wipo Patent WO/2006/133825 (date: 21.12.2006).

Willmann S, Edginton AN, Hoehn K, Schmitt W. Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis (Method for calculating and providing a drug dose - towards individualized dosing). Systems Biology, Bayer Technology Services, Leverkusen, Germany. Wipo Patent WO/2007/147539 (date: 27.12.2007).